Kewajiban jangka dawa marang ekuitas inozyme.com (INZY)

Inozyme Pharma, Inc. (INZY) attracts leading geneticists with a robust research foundation, supporting its staff with generous stock options. The company creates a unique environment for combating vascular calcification pathologies by offering an unrivaled therapy. The current metric stands at 0.69, as confirmed by the data illustrating the price evolution of the quote provided below for this biotech project.

Inozyme Pharma, Inc. (INZY) requires significant capital expenditures to develop innovative treatments for ENPP1 deficiency. The current long-term debt-to-equity ratio, standing at 0.69, reflects the financing structure of this research. This metric compares obligations with maturities exceeding one year against net shareholders' equity. The trend of this indicator allows for an assessment of financial leverage while awaiting regulatory approvals. A low value confirms the balance sheet's resilience ahead of the market launch of INZ-701.